Literature DB >> 32589307

Time-Limited Triplet Therapy Induces Rapid Undetectable MRD Responses in CLL.

.   

Abstract

Mesh:

Year:  2020        PMID: 32589307      PMCID: PMC7330921          DOI: 10.1634/theoncologist.2020-0558

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


× No keyword cloud information.
  2 in total

1.  Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Authors:  Nitin Jain; Michael Keating; Philip Thompson; Alessandra Ferrajoli; Jan Burger; Gautam Borthakur; Koichi Takahashi; Zeev Estrov; Nathan Fowler; Tapan Kadia; Marina Konopleva; Yesid Alvarado; Musa Yilmaz; Courtney DiNardo; Prithviraj Bose; Maro Ohanian; Naveen Pemmaraju; Elias Jabbour; Koji Sasaki; Rashmi Kanagal-Shamanna; Keyur Patel; Jeffrey Jorgensen; Naveen Garg; Xuemei Wang; Katrina Sondermann; Nichole Cruz; Chongjuan Wei; Ana Ayala; William Plunkett; Hagop Kantarjian; Varsha Gandhi; William Wierda
Journal:  N Engl J Med       Date:  2019-05-30       Impact factor: 91.245

2.  Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

Authors:  Kirsten Fischer; Othman Al-Sawaf; Jasmin Bahlo; Anna-Maria Fink; Maneesh Tandon; Mark Dixon; Sandra Robrecht; Simon Warburton; Kathryn Humphrey; Olga Samoylova; Anna M Liberati; Javier Pinilla-Ibarz; Stephen Opat; Liliya Sivcheva; Katell Le Dû; Laura M Fogliatto; Carsten U Niemann; Robert Weinkove; Sue Robinson; Thomas J Kipps; Sebastian Boettcher; Eugen Tausch; Rod Humerickhouse; Barbara Eichhorst; Clemens-Martin Wendtner; Anton W Langerak; Karl-Anton Kreuzer; Matthias Ritgen; Valentin Goede; Stephan Stilgenbauer; Mehrdad Mobasher; Michael Hallek
Journal:  N Engl J Med       Date:  2019-06-04       Impact factor: 91.245

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.